###begin article-title 0
Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during inflammation
###end article-title 0
###begin p 1
###xml 33 69 33 69 <email xmlns:xlink="http://www.w3.org/1999/xlink">markus.sperandio@med.uni-muenchen.de</email>
CORRESPONDENCE Markus Sperandio: markus.sperandio@med.uni-muenchen.de
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 195 207 195 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J. Exp. Med.</italic>
###xml 603 606 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 764 767 760 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 852 855 848 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 951 954 947 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1256 1273 1248 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Maackia amurensis</italic>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 1018 1023 <span type="species:ncbi:9606">human</span>
###xml 1256 1273 <span type="species:ncbi:37501">Maackia amurensis</span>
Recent in vitro studies have suggested a role for sialylation in chemokine receptor binding to its ligand (Bannert, N., S. Craig, M. Farzan, D. Sogah, N.V. Santo, H. Choe, and J. Sodroski. 2001. J. Exp. Med. 194:1661-1673). This prompted us to investigate chemokine-induced leukocyte adhesion in inflamed cremaster muscle venules of alpha2,3 sialyltransferase (ST3Gal-IV)-deficient mice. We found a marked reduction in leukocyte adhesion to inflamed microvessels upon injection of the CXCR2 ligands CXCL1 (keratinocyte-derived chemokine) or CXCL8 (interleukin 8). In addition, extravasation of ST3Gal-IV-/- neutrophils into thioglycollate-pretreated peritoneal cavities was significantly decreased. In vitro assays revealed that CXCL8 binding to isolated ST3Gal-IV-/- neutrophils was markedly impaired. Furthermore, CXCL1-mediated adhesion of ST3Gal-IV-/- leukocytes at physiological flow conditions, as well as transendothelial migration of ST3Gal-IV-/- leukocytes in response to CXCL1, was significantly reduced. In human neutrophils, enzymatic desialylation decreased binding of CXCR2 ligands to the neutrophil surface and diminished neutrophil degranulation in response to these chemokines. In addition, binding of alpha2,3-linked sialic acid-specific Maackia amurensis lectin II to purified CXCR2 from neuraminidase-treated CXCR2-transfected HEK293 cells was markedly impaired. Collectively, we provide substantial evidence that sialylation by ST3Gal-IV significantly contributes to CXCR2-mediated leukocyte adhesion during inflammation in vivo.
###end p 3
###begin p 4
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 110 111 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 189 206 185 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Maackia amurensis</italic>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 189 206 <span type="species:ncbi:37501">Maackia amurensis</span>
Abbreviations used: CF-CXCL8, human carboxyfluorescein-labeled CXCL8; fMLP, N-formyl-Met-Leu-Phe; GPCR, Galphai protein-coupled receptor; ICAM-1, intercellular adhesion molecule 1; MAL-II, Maackia amurensis lectin II; PTx, pertussis toxin; ST3Gal-IV, alpha2,3 sialyltransferase; WBC, white blood cell.
###end p 4
###begin p 5
D. Frommhold and A. Ludwig contributed equally to this work.
###end p 5
###begin p 6
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 611 612 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 674 675 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 811 812 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 1019 1020 1016 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1254 1255 1247 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 734 739 <span type="species:ncbi:9606">human</span>
###xml 930 935 <span type="species:ncbi:10090">mouse</span>
The recruitment of neutrophils into inflamed tissue is an important immunological process that proceeds along a well-defined cascade of events beginning with the capture of neutrophils to the inflamed endothelium and followed by neutrophil rolling along the endothelium (1). Both capture and rolling are mediated by selectins binding to selectin ligands (2). During rolling, neutrophils are in intimate contact with the inflamed endothelium, enabling endothelial-bound chemokines to interact with specific chemokine receptors expressed on the surface of neutrophils. This in turn triggers the activation of beta2 integrins, which eventually leads to firm neutrophil arrest (3). The CXC chemokine CXCL8 has been demonstrated to induce human neutrophil arrest from neutrophil rolling in a dynamic in vitro assay (4). Using intravital microscopy, a subsequent report demonstrated that triggering of neutrophil arrest in unstimulated mouse cremaster muscle venules was almost completely dependent on CXCR2-mediated events (5). In contrast, stimulating the cremaster muscle by intrascrotal injection of TNF-alpha led to neutrophil arrest, which was not strictly dependent on CXCR2 but occurred in an overlapping fashion with an E-selectin-mediated mechanism (5).
###end p 6
###begin p 7
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 713 714 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1429 1431 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1827 1829 1816 1818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1950 1953 1939 1942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2140 2142 2129 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 2144 2146 2133 2135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 732 737 <span type="species:ncbi:9606">human</span>
###xml 1745 1749 <span type="species:ncbi:10090">mice</span>
###xml 1954 1958 <span type="species:ncbi:10090">mice</span>
During leukocyte recruitment, an essential role of posttranslational glycosylation has been identified for selectin ligand function. This became particularly apparent in mice with a genetic deletion in glycosyltransferases such as fucosyltransferase VII or core 2 GlcNAcT-I (6, 7). Both enzymes are critically involved in the synthesis of core 2-decorated O-glycans carrying the selectin binding motif sialyl Lewis X as a capping group. Deletion of these enzymes led to a profound impairment of selectin-dependent leukocyte rolling in vivo (6, 8). Recently, it has been demonstrated that posttranslational glycosylation also influences the function of chemokine receptors (9, 10). Ludwig et al. demonstrated that N-glycosylation of human CXCR2 protects this receptor from proteolytic degradation and removal from the surface of neutrophils, whereas it does not interfere with its trafficking function (9). Bannert et al. used a canine thymocyte cell line to generate cells stably expressing WT CCR5 and CCR5 mutants. In CCR5 mutants, serine or threonine residues were changed to alanine at putative O-glycosylation sites at the N terminus of CCR5 (10). Functional analysis of the cell lines carrying the different CCR5 mutants revealed that CCR5 binding to the CC chemokines macrophage inflammatory proteins 1alpha and 1beta was strongly dependent on a sialic acid carrying O-glycan linked to serine 6 at the N terminus of CCR5 (10). Although these findings point toward an important role of glycosylation and sialylation in the function of some chemokine receptors, the contribution of distinct glycosyltransferases in the proper synthesis of carbohydrate structures crucial for chemokine receptor function has not been investigated. Recently, mice deficient in the alpha2,3 sialyltransferase (ST3Gal-IV) have been generated (11). In vivo studies on P-, E-, and L-selectin-mediated leukocyte rolling in inflamed cremaster muscle venules of ST3Gal-IV-/- mice revealed a complete absence of L-selectin ligand function and a partial impairment in E-selectin-dependent leukocyte rolling, whereas P-selectin-dependent rolling was not affected (12, 13).
###end p 7
###begin p 8
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 579 582 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
In this study, we will present substantial evidence that leukocyte adhesion and extravasation are impaired in ST3Gal-IV-/- mice. Because of the rather mild defect at the level of leukocyte rolling, the impairment in leukocyte adhesion and extravasation in ST3Gal-IV-/- mice cannot be explained by the observed rolling defect. We therefore hypothesized that sialylation by ST3Gal-IV contributes to chemokine-triggered neutrophil arrest in vivo. To this end, we investigated leukocyte arrest mechanisms in unstimulated and TNF-alpha-stimulated cremaster muscle venules of ST3Gal-IV-/- mice in vivo and in various static and dynamic assays in vitro.
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
Leukocyte adhesion in trauma-induced inflammation
###end title 10
###begin p 11
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 521 524 521 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 607 610 607 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 617 625 617 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 905 906 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1158 1165 1158 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 1246 1247 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1296 1297 1292 1293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1311 1319 1307 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1394 1397 1390 1393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1439 1440 1433 1434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1488 1489 1480 1481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1513 1521 1505 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1737 1738 1724 1725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 1841 1842 1828 1829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1994 1995 1979 1980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2045 2053 2030 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 2161 2162 2144 2145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2177 2180 2160 2163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2346 2347 2325 2326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2363 2371 2342 2350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 2466 2469 2445 2448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2587 2592 2566 2571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 2662 2665 2641 2644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2753 2754 2728 2729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2768 2776 2743 2751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
###xml 1023 1028 <span type="species:ncbi:9606">human</span>
###xml 1067 1072 <span type="species:ncbi:10090">mouse</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
###xml 1665 1669 <span type="species:ncbi:10090">mice</span>
###xml 1876 1880 <span type="species:ncbi:10090">mice</span>
###xml 2027 2031 <span type="species:ncbi:10090">mice</span>
###xml 2112 2116 <span type="species:ncbi:10090">mice</span>
###xml 2181 2185 <span type="species:ncbi:10090">mice</span>
###xml 2470 2474 <span type="species:ncbi:10090">mice</span>
###xml 2593 2597 <span type="species:ncbi:10090">mice</span>
###xml 2666 2670 <span type="species:ncbi:10090">mice</span>
###xml 2842 2846 <span type="species:ncbi:10090">mice</span>
Leukocyte adhesion was assessed in 58 cremaster muscle venules of 13 ST3Gal-IV-/- mice and compared with leukocyte adhesion in 37 venules of 13 WT control mice. Hemodynamic parameters between the groups showed no significant difference in vascular diameter, blood flow velocity, wall shear rate, and systemic white blood cell (WBC) count (Table I). Leukocyte adhesion in postcapillary venules of the cremaster muscle during the first hour after exteriorization of the cremaster muscle was significantly lower in ST3Gal-IV-/- than in WT control mice, suggesting a defect in firm leukocyte arrest in ST3Gal-IV-/- mice (Fig. 1 A). As recently demonstrated, leukocyte adhesion in untreated cremaster muscle venules is mediated via interactions between chemokine receptor CXCR2 expressed on the surface of rolling neutrophils and endothelial-bound chemokines, including keratinocyte-derived chemokine (CXCL1) (5). We analyzed leukocyte adhesion in untreated mice before and 3 min after systemic injection of 600 ng CXCL1 or the human prototype CXC chemokine CXCL8 (600 ng/mouse). Microvascular parameters during those experiments were similar between the groups (Table I). In WT mice, the number of adherent leukocytes increased by 457 +/- 83 cells/mm2 after CXCL1 injection and by 422 +/- 87 cells/mm2 after CXCL8 (Fig. 1 B; and Video 1, available at ). In contrast, leukocyte adhesion in ST3Gal-IV-/- mice increased only by 73 +/- 17 cells/mm2 after CXCL1 injection and by 73 +/- 34 cells/mm2 after CXCL8 injection (Fig. 1 B; and Video 2), suggesting that CXCL1- and CXCL8-induced firm adhesion are dependent on ST3Gal-IV. Next, leukocyte adhesion was investigated in mice pretreated with 4 mug pertussis toxin (PTx), an inhibitor of Galphai protein-coupled receptors, 3 h before cremaster muscle exteriorization. Similar to a previous report (5), PTx pretreatment of WT control mice led to a significant attenuation in the increase of adherent leukocytes after CXCL1 injection (83 +/- 21 cells/mm2) when compared with WT control mice without PTx (Fig. 1 B). Similar results were obtained in PTx-pretreated control mice after injection of CXCL8 (88 +/- 33 cells/mm2). In ST3Gal-IV-/- mice, no significant influence of PTx pretreatment was noted on the number of accumulated leukocytes after CXCL1 or CXCL8 injection (45 +/- 27 and 88 +/- 40 cells/mm2, respectively; Fig. 1 B), suggesting that leukocyte adhesion triggered by CXCR2 is significantly impaired in ST3Gal-IV-/- mice. Finally, we investigated the increase in the number of adherent leukocytes in cremaster muscle venules of CXCR2bm-/- mice after systemic injection of CXCL1 or CXCL8. Similar to ST3Gal-IV-/- mice, leukocyte adhesion after CXCL1 increased only by 80 +/- 16 and 88 +/- 41 cells/mm2 after CXCL8 (Fig. 1 B). This was significantly different to the results observed in WT mice, demonstrating that CXCR2 is crucial in mediating CXCL1/CXCL8-dependent leukocyte adhesion in this setting.
###end p 11
###begin p 12
###xml 132 135 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 142 147 140 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
Hemodynamic parameters (mean +/- SEM of diameter, centerline velocity, shear rate, and WBC) of cremaster muscle venules in ST3Gal-IV-/-, CXCR2bm-/-, and WT control mice
###end p 12
###begin p 13
n.s., nonsignificant (P > 0.05).
###end p 13
###begin p 14
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Leukocyte adhesion during inflammation in vivo.</bold>
###xml 102 103 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 195 198 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 275 276 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 374 377 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 417 420 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 448 453 442 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 647 650 635 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 661 666 649 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 742 745 726 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 756 761 740 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 975 979 <span type="species:ncbi:10090">mice</span>
###xml 1021 1025 <span type="species:ncbi:10090">mice</span>
Leukocyte adhesion during inflammation in vivo. (A) Number of adherent leukocytes (mean +/- SEM per mm2 of surface area) in unstimulated mouse cremaster muscle venules of WT control and ST3Gal-IV-/- mice. (B) Increase in the number of adherent leukocytes (mean +/- SEM per mm2 of surface area) 3 min after systemic injection of 600 ng CXCL1 or CXCL8 in WT control, ST3Gal-IV-/-, WT control (plus 4 mug PTx), ST3Gal-IV-/- (plus 4 mug PTx), and CXCR2bm-/- mice. PTx was injected 3 h before cremaster muscle exteriorization. (C) Leukocyte adhesion (mean +/- SEM) was observed in 3-h TNF-alpha-treated cremaster muscle venules of WT control, ST3Gal-IV-/-, and CXCR2bm-/- mice. Additionally, pretreatment of TNF-alpha-treated WT control, ST3Gal-IV-/-, and CXCR2bm-/- mice was conducted with 4 mug PTx and/or 100 mug E-selectin mAb 9A9 5 min before TNF-alpha injection. Data in A-C were obtained from at least three independent experiments per group. *, P < 0.05 versus WT control mice (A and C); *, P < 0.05 versus WT control mice treated with CXCL1 or CXCL8, respectively (B). Videos 1 and 2 are available at .
###end p 14
###begin p 15
###xml 140 143 140 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 153 158 153 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 274 279 274 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 394 399 392 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 530 533 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 543 548 537 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
To exclude the possibility that a reduction in leukocyte rolling is responsible for the impaired firm leukocyte arrest observed in ST3Gal-IV-/- and CXCR2bm-/- mice, we assessed leukocyte rolling in unstimulated cremaster muscle venules of WT control, ST3Gal-IV-/-, and CXCR2bm-/- mice. We found a significant increase in the leukocyte rolling flux fraction in ST3Gal-IV-/- (46 +/- 5%) and CXCR2bm-/- (51 +/- 7%) mice compared with control mice (32 +/- 4%; P < 0.05; Fig. S1 A, available at ), reflecting the inability of ST3Gal-IV-/- and CXCR2bm-/- leukocytes to transit from established rolling into firm arrest.
###end p 15
###begin title 16
Leukocyte adhesion in TNF-alpha-induced inflammation
###end title 16
###begin p 17
###xml 107 110 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 144 149 140 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 393 394 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 454 461 446 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 646 647 632 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 659 662 645 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 683 684 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 696 701 680 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 722 723 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 731 739 713 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 923 924 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 940 948 918 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 951 952 929 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 975 978 953 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 987 992 965 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1094 1095 1068 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1164 1167 1138 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1176 1181 1150 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1314 1315 1284 1285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1356 1364 1326 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1491 1494 1461 1464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1552 1555 1522 1525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1565 1570 1535 1540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1718 1719 1684 1685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1735 1743 1701 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1903 1904 1867 1868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1906 1914 1870 1878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1182 1186 <span type="species:ncbi:10090">mice</span>
###xml 1396 1400 <span type="species:ncbi:10090">mice</span>
###xml 1495 1499 <span type="species:ncbi:10090">mice</span>
###xml 1571 1575 <span type="species:ncbi:10090">mice</span>
###xml 1773 1777 <span type="species:ncbi:10090">mice</span>
Next, we observed leukocyte adhesion in 90 TNF-alpha-treated (3 h) cremaster muscle venules of 16 ST3Gal-IV-/- mice and in 76 venules of 8 CXCR2bm-/- mice, and compared it with leukocyte adhesion in 67 venules of 16 WT animals. In this model, transition from leukocyte rolling to firm adhesion after TNF-alpha pretreatment is mediated in an overlapping fashion involving CXCR2 and E-selectin (5). Microvascular parameters for the groups are presented in Table I and show similar vessel diameters, centerline velocities, wall shear rates, and WBC counts. Leukocyte adhesion 3 h after TNF-alpha treatment was similar between WT (674 +/- 80 cells/mm2), ST3Gal-IV-/- (759 +/- 66 cells/mm2), and CXCR2bm-/- (717 +/- 68 cells/mm2) mice (Fig. 1 C). In agreement with a previous study, pretreatment with the E-selectin blocking mAb 9A9 or PTx did not affect neutrophil arrest in WT control mice (799 +/- 128 and 823 +/- 91 cells/mm2, respectively; Fig. 1 C) (5). Similarly, ST3Gal-IV-/- or CXCR2bm-/- mice pretreated with PTx revealed no changes in neutrophil arrest (821 +/- 78 and 686 +/- 47 cells/mm2, respectively) compared with WT control mice. In contrast, ST3Gal-IV-/- or CXCR2bm-/- mice pretreated with E-selectin blocking mAb 9A9 showed significantly reduced leukocyte adhesion (308 +/- 56 and 239 +/- 31 cells/mm2, respectively; P < 0.05 vs. WT control; Fig. 1 C) when compared with WT control mice, suggesting that leukocyte arrest triggered by CXCR2 is considerably affected in ST3Gal-IV-/- mice. This was also supported by experiments in ST3Gal-IV-/- and CXCR2bm-/- mice pretreated with both PTx and E-selectin blocking mAb 9A9, where leukocyte adhesion was not further reduced (324 +/- 45 and 295 +/- 30 cells/mm2, respectively; Fig. 1 C). In addition, in WT control mice pretreated with PTx and E-selectin blocking mAb 9A9, leukocyte adhesion was also significantly decreased (304 +/- 54 cells/mm2; Fig. 1 C), confirming the crucial role of ST3Gal-IV for firm leukocyte adhesion in vivo.
###end p 17
###begin p 18
###xml 52 55 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 66 71 66 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 201 204 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 226 231 220 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
Next, we assessed leukocyte rolling in WT, ST3Gal-IV-/-, and CXCR2bm-/- mice. We found no difference in the leukocyte rolling flux fraction in TNF-alpha-stimulated cremaster muscle venules of ST3Gal-IV-/- (21 +/- 4%) and CXCR2bm-/- (15 +/- 2%) mice compared with WT control mice (20 +/- 3%; Fig. S1 B).
###end p 18
###begin title 19
Leukocyte adhesion and extravasation in whole mounts of TNF-alpha-treated cremaster muscles
###end title 19
###begin p 20
###xml 284 287 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 297 302 293 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 407 418 403 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, A&#8211;C</xref>
###xml 557 560 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 624 627 620 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 727 730 719 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 739 744 731 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 765 766 753 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink">I</sub>
###xml 901 907 889 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
To investigate the contribution of ST3Gal-IV on the composition and number of extravasated neutrophils, we performed Giemsa staining of whole-mount cremaster muscles pretreated with TNF-alpha and classified leukocytes into neutrophils, eosinophils, and mononuclear cells. In ST3Gal-IV-/- and CXCR2bm-/- mice, the number of intravascular and extravasated neutrophils was similar to that observed in WT mice (Fig. 2, A-C). Relative frequencies of intravascular and extravasated neutrophils, mononuclear cells, and eosinophils were comparable between ST3Gal-IV-/- and WT mice, suggesting that leukocyte recruitment in ST3Gal-IV-/- mice is not impaired after stimulation with TNF-alpha (unpublished data). Pretreatment of ST3Gal-IV-/- or CXCR2bm-/- mice with the GalphaI blocker PTx did not significantly influence the number of intra- and extravascular leukocytes nor the relative leukocyte frequencies (Fig. 2; unpublished data).
###end p 20
###begin p 21
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cremaster muscle whole mount.</bold>
###xml 113 116 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 127 132 123 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 240 241 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 455 458 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
Cremaster muscle whole mount. Giemsa-stained whole-mounts of TNF-alpha-treated cremaster muscles of WT, ST3Gal-IV-/-, and CXCR2bm-/- mice were analyzed for the number of intravascular (A) and perivascular (B) leukocytes (mean +/- SEM per mm2 surface area). In addition, two typical micrographs are presented illustrating intra- and perivascular leukocyte distribution in TNF-alpha-treated cremaster muscle whole mounts of WT control mice (C) and ST3Gal-IV-/- mice pretreated with E-selectin blocking mAb 9A9 (D). Data in A and B were obtained from at least three independent experiments per group. *, P < 0.05 versus WT mice. Bars, 50 mum.
###end p 21
###begin p 22
###xml 133 136 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 375 390 371 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, A and B</xref>
###xml 577 580 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 745 756 741 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, A&#8211;D</xref>
###xml 862 865 858 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1110 1115 1106 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1178 1193 1174 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, A and B</xref>
###xml 1321 1324 1317 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 510 514 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 917 921 <span type="species:ncbi:10090">mice</span>
###xml 1116 1120 <span type="species:ncbi:10090">mice</span>
###xml 1325 1329 <span type="species:ncbi:10090">mice</span>
Next, we investigated the number of intra- and perivascular neutrophils in TNF-alpha-stimulated cremaster muscle venules of ST3Gal-IV-/- and WT control mice pretreated with the E-selectin blocking mAb 9A9. Blocking E-selectin in WT control mice did not change the number of intravascular neutrophils nor neutrophil extravasation when compared with untreated WT control mice (Fig. 2, A and B). In addition, the composition of perivascular leukocytes was similar between E-selectin mAb 9A9-pretreated WT control mice and untreated WT control mice (unpublished data). In ST3Gal-IV-/- mice pretreated with the E-selectin blocking mAb 9A9, intravascular as well as perivascular neutrophils were significantly decreased compared with WT control mice (Fig. 2, A-D). However, the composition of extravasated leukocytes in E-selectin blocking mAb 9A9-pretreated ST3Gal-IV-/- mice did not significantly change compared with WT mice, suggesting that the emigration of mononuclear cells and eosinophils was also impaired (unpublished data). Next, we investigated intra- and perivascular neutrophils in WT control and CXCR2bm-/- mice pretreated with the E-selectin blocking mAb 9A9 and PTx (Fig. 2, A and B). We found a similar reduction in the number of perivascular neutrophils as in E-selectin blocking mAb 9A9-pretreated ST3Gal-IV-/- mice, confirming that ST3Gal-IV is involved in CXCR2-dependent extravasation of neutrophils.
###end p 22
###begin title 23
Thioglycollate-induced peritonitis
###end title 23
###begin p 24
###xml 79 80 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 265 266 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 337 340 333 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 351 356 347 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 483 486 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 501 502 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 510 511 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 517 523 513 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 573 574 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 582 583 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 609 614 605 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 629 630 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 638 639 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 681 682 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 690 691 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 789 792 785 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 873 876 869 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1005 1006 1001 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1014 1015 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1021 1027 1017 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
As reported previously, neutrophil arrest inhibition through blockade of Galphai protein-coupled receptor (GPCR)-dependent signals leads to impaired extravasation of neutrophils into the inflamed peritoneal cavity after intraperitoneal injection of thioglycollate (5). We investigated neutrophil influx into the peritoneum of WT, ST3Gal4-/-, and CXCR2bm-/- mice 4 h after thioglycollate injection. Neutrophil recruitment to the peritoneum was significantly reduced to 60% in ST3GalIV-/- mice (4.5 x 106 cells; n = 9; Fig. 3), to 57% in WT mice pretreated with PTx (4.3 x 106 cells; n = 6), and to 35% in CXCR2bm-/- mice (2.5 x 106 cells; n = 3) when compared with WT mice (7.5 x 106 cells; n = 7; P < 0.05). These results suggest that chemokine-triggered signaling is impaired in ST3Gal-IV-/- mice, which was also confirmed by the observation that pretreatment of ST3Gal-IV-/- mice with PTx did not cause a further significant reduction in neutrophil extravasation after thioglycollate injection (2.7 x 106 cells; n = 5; Fig. 3).
###end p 24
###begin p 25
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Thioglycollate-induced peritonitis.</bold>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 145 148 145 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 178 179 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 195 198 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 216 217 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 233 238 231 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 240 241 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 283 284 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
Thioglycollate-induced peritonitis. Peritoneal neutrophil influx was assessed 4 h after injection of 4% thioglycollate into WT (n = 7), ST3Gal-IV-/- (n = 9), WT (plus 4 mug PTx; n = 6), ST3Gal-IV-/- (plus 4 mug PTx; n = 5), and CXCR2bm-/- (n = 3) mice. The number of neutrophils (x106; mean +/- SEM) was assessed from Turks-stained peritoneal lavage samples. *, P < 0.05 versus WT control mice.
###end p 25
###begin title 26
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
Ligand binding and functional activity of CXCR2 on ST3Gal-IV-/- neutrophils
###end title 26
###begin p 27
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 270 273 270 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 459 462 459 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 484 492 484 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 544 547 544 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 629 632 629 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1075 1077 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1171 1179 1171 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1373 1378 1373 1378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1385 1393 1385 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1454 1457 1454 1457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
###xml 850 855 <span type="species:ncbi:9606">human</span>
###xml 1009 1014 <span type="species:ncbi:10090">mouse</span>
###xml 1022 1027 <span type="species:ncbi:9606">Human</span>
###xml 1062 1067 <span type="species:ncbi:10090">mouse</span>
###xml 1194 1199 <span type="species:ncbi:9606">Human</span>
###xml 1251 1256 <span type="species:ncbi:10090">mouse</span>
###xml 1379 1383 <span type="species:ncbi:10090">mice</span>
###xml 1458 1462 <span type="species:ncbi:10090">mice</span>
###xml 1799 1804 <span type="species:ncbi:10090">mouse</span>
Because CXCR2 was found to carry several N-glycosylation sites with potential terminal sialylation (9), we tested whether deficiency of ST3Gal-IV would directly affect the biology of this receptor. To address the possibility that a lower expression of CXCR2 on ST3Gal-IV-/- leukocytes contributes to the decrease in the number of adherent leukocytes, we initially performed flow cytometric analysis of CXCR2 expression on GR-1-positive leukocytes of ST3Gal-IV-/- and WT control mice (Fig. 4 A). CXCR2 expression was slightly higher in ST3Gal-IV-/- compared with WT control mice, excluding a lower expression of CXCR2 in ST3Gal-IV-/- mice to be responsible for the observed defect in leukocyte adhesion in these mice. We then questioned whether ST3Gal-IV deficiency would affect ligand binding to CXCR2. For the ligand binding assays, we chose to use human carboxyfluorescein-labeled CXCL8 (CF-CXCL8), because bound CF-CXCL8 can be directly detected by flow cytometric analysis of leukocyte populations within mouse blood. Human CXCL8 binds with high affinity to mouse CXCR2 (14) and exerts the same in vivo effect as CXCL1 when injected into WT cremaster muscle venules (Fig. 1 B and Video 1). Human CXCL8 can therefore be used for binding studies in mouse neutrophils. The specificity of CF-CXCL8 binding was demonstrated by its decreased binding to neutrophils from CXCR2bm-/- mice (Fig. 4 B) When compared with WT leukocytes, leukocytes from ST3Gal-IV-/- mice showed a considerably reduced ability to bind CF-CXCL8. A reduction in CF-CXCL8 binding was also observed when WT neutrophils were treated with neuraminidase, which removes terminal sialic acids from surface glycoproteins. These data point toward a role of alpha2,3-linked sialic acid residues for efficient binding of CXCR2 ligands to mouse neutrophils.
###end p 27
###begin p 28
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CXCR2 expression and ligand binding of ST3Gal-IV<sup>&#8722;/&#8722;</sup> leukocytes.</bold>
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 408 411 408 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 413 414 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 430 435 430 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 437 438 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 765 768 763 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 775 780 773 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 605 609 <span type="species:ncbi:10090">mice</span>
CXCR2 expression and ligand binding of ST3Gal-IV-/- leukocytes. (A) Surface expression of CXCR2 on GR-1-positive leukocytes of ST3Gal-IV-/- and WT mice was analyzed by flow cytometry. Leukocytes were incubated with an allophycocyanin-labeled GR-1 mAb, a PE-labeled anti-CXCR2 mAb, and a PE-labeled isotype control. (B) For ligand binding studies, leukocytes from the peripheral blood of WT (n = 4), ST3Gal-IV-/- (n = 3), and CXCR2bm-/- (n = 3) mice were incubated with different dilutions of CF-CXCL8 and subsequently analyzed for bound fluorescence by flow cytometry. Peripheral blood leukocytes from WT mice were treated with 100 mU/ml neuraminidase for 60 min and investigated for CF-CXCL8 binding. Data are given as mean +/- SD. P < 0.05 for WT versus ST3Gal-IV-/-, CXCR2bm-/-, and WT + Neu for 30 and 90 nM CF-CXCL8, respectively. MFI, mean fluorescence intensity.
###end p 28
###begin title 29
###xml 31 34 31 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
Leukocyte adhesion in ST3Gal-IV-/- neutrophils in the microflow chamber assay
###end title 29
###begin p 30
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 427 435 427 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 657 665 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 683 691 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 858 861 858 861 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1119 1127 1119 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 153 158 <span type="species:ncbi:10090">mouse</span>
###xml 862 866 <span type="species:ncbi:10090">mice</span>
Next, we investigated the role of ST3Gal-IV on leukocyte arrest using a recently described autoperfused microflow chamber system coated with recombinant mouse P-selectin, intercellular adhesion molecule 1 (ICAM-1), and CXCL1 (15). This combination of proteins mediates rolling and firm arrest of WT neutrophils (15). Rolling of WT and ST3Gal-IV-/- leukocytes was noted in all flow chambers in which P-selectin was immobilized (Fig. 5 A). However, a marked reduction in the rolling of control leukocytes was noted in the presence of ICAM-1 and CXCL1, which was most likely caused by the concomitant significant increase in the number of adherent leukocytes (Fig. 5 A). As depicted in Fig. 5 B, adhesion of WT leukocytes was only observed in flow chambers in which all three molecules (P-selectin, ICAM-1, and CXCL1) were immobilized. Leukocytes from ST3Gal-IV-/- mice also firmly adhered only in those flow chambers in which P-selectin, ICAM-1, and CXCL1 were immobilized on the surface. However, the number of adherent leukocytes was significantly lower than observed with control leukocytes under the same conditions (Fig. 5 B). These results strongly suggest that ST3Gal-IV significantly contributes to the successful arrest of leukocytes in the presence of CXCL1, ICAM-1, and P-selectin.
###end p 30
###begin p 31
###xml 60 63 60 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Adhesion in the flow chamber and transmigration of ST3Gal-IV<sup>&#8722;/&#8722;</sup> neutrophils in vitro.</bold>
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 594 597 589 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
Adhesion in the flow chamber and transmigration of ST3Gal-IV-/- neutrophils in vitro. The number of rolling and adherent leukocytes from ST3Gal-IV-/- and WT mice was determined in blood-perfused microflow chambers. (A) Rolling and (B) adherent leukocytes in autoperfused flow chambers (5.94 dynes/cm2) coated with 20 mug/ml P-selectin and 15 mug/ml ICAM-1 with or without 15 mug/ml CXCL1. Data in A and B are presented as mean +/- SEM from at least four mice and four flow chambers. *, P < 0.05 versus WT mice (B). (C) The percentage of transmigrated neutrophils from WT control mice, ST3Gal-IV-/- mice, and WT control mice pretreated with neuraminidase was assessed in a transwell assay in which transwells were coated with an immortalized endothelial cell line, b.End5. In addition, transmigration of WT control neutrophils through a neuraminidase-pretreated b.End5 monolayer was analyzed. Data in C were determined from at least three independent experiments per group. *, P < 0.05 versus untreated WT control neutrophils (C). FOV, field of view.
###end p 31
###begin title 32
Transendothelial migration of neutrophils
###end title 32
###begin p 33
###xml 145 148 145 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 246 254 246 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 471 479 471 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 817 820 813 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 938 946 930 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 1167 1170 1159 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1202 1203 1192 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1226 1227 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 821 825 <span type="species:ncbi:10090">mice</span>
To study the contribution of neutrophil-expressed ST3Gal-IV on neutrophil transmigration, CXCL1-triggered transendothelial migration of ST3Gal-IV-/- neutrophils through an endothelial cell line monolayer (b.End5) was investigated. As depicted in Fig. 5 C, transendothelial migration was significantly reduced for ST3GalIV-/- compared with WT neutrophils. In addition, transendothelial migration of neuraminidase-pretreated control neutrophils was also markedly impaired (Fig. 5 C), suggesting that alpha2,3 sialylation by ST3Gal-IV is important for CXCL1-induced neutrophil transmigration. Pretreatment of the endothelial cell line b.End5 with neuraminidase before addition of WT neutrophils did not reduce the number of migrated neutrophils, suggesting that the impairment in neutrophil recruitment seen in ST3Gal-IV-/- mice is caused by the loss of crucial alpha2,3-linked sialic acid residues on neutrophils, not on endothelial cells (Fig. 5 C). To rule out any significant effect of CXCL1-independent transmigration, we also performed transmigration experiments without CXCL1. Spontaneous neutrophil transmigration (without CXCL1) was similar for WT and ST3Gal-IV-/- neutrophils (0.07 +/- 0.04 x 106 vs. 0.06 +/- 0.01 x 106 cells, respectively) and accounted for 20 and 17% of migrated neutrophils, respectively, compared with the total number of migrated WT neutrophils observed during CXCL1-induced transmigration (unpublished data).
###end p 33
###begin title 34
###xml 74 79 <span type="species:ncbi:9606">human</span>
Effect of enzymatic desialylation on the binding and activity of CXCR2 on human neutrophils
###end title 34
###begin p 35
###xml 214 231 214 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Maackia amurensis</italic>
###xml 387 389 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 551 559 547 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 792 800 788 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 214 231 <span type="species:ncbi:37501">Maackia amurensis</span>
###xml 760 765 <span type="species:ncbi:10090">mouse</span>
Biochemical studies on the presence of terminal sialic acids on CXCR2 were performed with human CXCR2, which could be precipitated from CXCR2-transfected HEK293 cells and subsequently probed for the binding of the Maackia amurensis lectin II (MAL-II), which preferentially recognizes carbohydrate chains containing sialic acid residues alpha2,3 linked to penultimate galactose residues (16). Digestion of precipitates with neuraminidase clearly abolished MAL-II binding but not detection of CXCR2, indicating that CXCR2 carries terminal sialic acids (Fig. 6 A). In addition, binding of CF-CXCL8 to HEK293 cells was clearly dependent on the presence of CXCR2, because CF-CXCL8 did not bind to untransfected HEK293 cells (unpublished data). However, as seen for mouse neutrophils (compare with Fig. 4 B), binding was considerably reduced (by 46%; not depicted) when the cells were desialylated by treatment with neuraminidase.
###end p 35
###begin p 36
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of enzymatic desialylation on chemokine binding and function of human CXCR2.</bold>
###xml 615 618 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 638 641 626 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 860 865 <span type="species:ncbi:9606">human</span>
Effect of enzymatic desialylation on chemokine binding and function of human CXCR2. (A) Cell lysates of CXCR2-transfected and untransfected HEK293 cells were incubated with an mAb to CXCR2, followed by precipitation with protein A. Precipitates were treated with 20 U/ml neuraminidase for 60 min at 37degreesC, or were left untreated and analyzed by Western blotting for binding of biotinylated anti-CXCR2 antibody or biotinylated MAL-II, respectively. (B) Isolated human neutrophils were treated with the indicated dosages of neuraminidase for 30 min at 37degreesC, washed, and subsequently assayed for binding of 125I-labeled CXCL7 and 125I-labeled CXCL4. Specifically bound radioactivity was expressed as the percentage of WT control cells receiving no enzyme treatment. (C) Scatchard plot for CXCL7 binding to untreated and neuraminidase-treated (20 U/ml) human neutrophils. The binding data were curve fit to determine affinity constants for high and low affinity binding sites. (D) Neutrophils were treated with the indicated dosages of neuraminidase for 30 min at 37degreesC, washed, and subsequently assayed for elastase release in response to increasing concentrations of CXCL7, CXCL8, and fMLP. The residual responsiveness of neuraminidase-treated neutrophils was expressed as the percentage of that determined for untreated cells. Data in A-D represent means +/- SD determined in three different experiments, each with blood from a different donor.
###end p 36
###begin p 37
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 851 859 851 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1270 1278 1270 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
To address whether terminal sialylation is also implicated in the ligand binding and function of CXCR2 on human neutrophils, isolated human neutrophils were treated with different dosages of neuraminidase. As demonstrated by binding assays with the radioactively labeled CXCR2 ligand 125I-labeled neutrophil-activating peptide 2 (CXCL7), treatment with neuraminidase resulted in reduced binding of the chemokine to neutrophils (Fig. 6 B). For these experiments, CXCL7 was chosen as a radioligand, because this chemokine displays high affinity binding to CXCR2 and low affinity binding to CXCR1, whereas CXCL8 binds to both CXCR1 and CXCR2 with high affinity (17). Scatchard plot analysis revealed that CXCL7 binding to high affinity sites was shifted from 6.6 to 20 nM after neuraminidase treatment, whereas the low affinity binding was not affected (Fig. 6 C). The total number of binding sites was not changed upon treatment with neuraminidase, which was consistent with the unaffected expression level of CXCR2 and CXCR1 on the surface of these cells, as determined by flow cytometry (Fig. S2 A, available at ). Binding of platelet factor 4 (CXCL4), which is not dependent on either of the two receptors (CXCR1 or CXCR2), was not affected by neuraminidase treatment (Fig. 6 B).
###end p 37
###begin p 38
###xml 295 303 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 772 780 772 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 241 246 <span type="species:ncbi:9606">human</span>
Functionally, CXCL7 and CXCL8 induce lysosomal degranulation of neutrophils. We investigated the release of elastase from primary granules of CXCL8- and CXCL7-treated neutrophils and found that elastase release was considerably reduced when human neutrophils were pretreated with neuraminidase (Fig. 6 D). Notably, elastase release in response to the preferential CXCR2 ligand CXCL7 was more profoundly reduced than that after CXCL8 stimulation, which is explained by the fact that CXCL8 binds and functions via both CXCR1 and CXCR2 (17). Importantly, enzymatic digestion did not lead to a decreased reactivity of neutrophils in general, as stimulation with the tripeptide N-formyl-Met-Leu-Phe (fMLP) induced similar responses in untreated and enzyme-treated neutrophils (Fig. 6 D). These findings were further corroborated by measuring CXCL7-induced lactoferrin release from secondary granules, which was significantly diminished in neuraminidase-treated neutrophils (Fig. S2 B). In contrast, lactoferrin release triggered by CXCL4 (which does not bind to CXCR2) was not influenced by the enzymatic treatment (Fig. S2 B). Thus, terminal sialic acids are found on CXCR2, and deficient sialylation in neutrophils decreases ligand binding and activity of the receptor.
###end p 38
###begin title 39
DISCUSSION
###end title 39
###begin p 40
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
Chemokine receptors and their ligands are involved in many immunological processes requiring specific and high affinity interactions between chemokine receptors and their respective ligands (18-21). Specificity is in part achieved by posttranslational modification of chemokine receptors, as recently demonstrated for CXCR2 and CCR5 (9, 10).
###end p 40
###begin p 41
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
The chemokine receptor CXCR2 (mouse homologue of IL-8 receptor B) is involved in chemokine-induced leukocyte adhesion and migration (22-24). Two studies identified CXCR2 as playing a critical role during the pathogenesis of ventilator- or LPS-induced inflammatory lung injury (25, 26). In addition, CXCR2 was also shown to participate in the recruitment of macrophages into established atherosclerotic lesions (27).
###end p 41
###begin p 42
###xml 413 416 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 651 654 651 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 712 717 712 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 938 941 930 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 948 953 940 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1100 1101 1092 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1198 1201 1190 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1208 1213 1200 1205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1252 1255 1244 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1265 1270 1257 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 1448 1451 1440 1443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 970 974 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1271 1275 <span type="species:ncbi:10090">mice</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1452 1456 <span type="species:ncbi:10090">mice</span>
In contrast to the variety of publications illustrating CXCR2-mediated effects in a wide spectrum of diseases, little is known about how CXCR2 achieves specific binding to its ligands. We present for the first time in vivo evidence that CXCR2-triggered leukocyte arrest during inflammation is strongly dependent on posttranslational sialylation mediated by ST3Gal-IV. This can be deduced from results in ST3Gal-IV-/- mice, where baseline as well as CXCL1- or CXCL8-triggered leukocyte adhesion in trauma-induced inflammation was significantly lower than in WT control mice. However, leukocyte adhesion was comparable to either WT control and ST3Gal-IV-/- mice pretreated with PTx, an inhibitor of GPCRs, or CXCR2bm-/- mice, suggesting an important role for alpha2,3-sialylation in CXCR2 function in vivo. In a second approach, we found that leukocyte adhesion in TNF-alpha-stimulated cremaster muscle venules was similar between ST3Gal-IV-/-, CXCR2bm-/-, and WT control mice. In this model, leukocyte adhesion occurs in an overlapping fashion by E-selectin- and chemokine-triggered CXCR2 activation (5). Although blockade of GPCRs with PTx did not have any effect on leukocyte adhesion in ST3Gal-IV-/-, CXCR2bm-/-, or WT mice, pretreatment of ST3Gal-IV-/- and CXCR2bm-/- mice but not WT mice with E-selectin blocking mAb 9A9 led to a significant reduction of leukocyte adhesion, suggesting that CXCR2-triggered firm arrest is defective in ST3Gal-IV-/- mice.
###end p 42
###begin p 43
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 379 382 379 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 628 631 628 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 970 973 970 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1073 1076 1073 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 1300 1302 1300 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 290 295 <span type="species:ncbi:10090">mouse</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 632 636 <span type="species:ncbi:10090">mice</span>
###xml 776 781 <span type="species:ncbi:9606">human</span>
###xml 1128 1133 <span type="species:ncbi:9606">human</span>
To challenge our results and directly investigate CXCR2-dependent leukocyte adhesion in a more reductionist system in which all "endothelial players" are known, we used a recently described ex vivo flow chamber system and coated the surface of the rectangular flow chamber with recombinant mouse P-selectin, ICAM-1, and CXCL1 (15). Although we observed some adhesion of ST3Gal-IV-/- leukocytes in the flow chamber, the number of adherent cells was significantly lower than that seen in control mice. These data strongly support the hypothesis that CXCR2-mediated events leading to firm leukocyte arrest are impaired in ST3Gal-IV-/- mice. In addition, the results suggest that the adhesion defect is located on neutrophils. This observation was confirmed and expanded into the human system in direct ligand binding assays using fluorescently labeled CXCL8 and radiolabeled CXCL7. We found a significant and dose-dependent reduction in the binding of CF-CXCL8 to ST3Gal-IV-/- neutrophils when compared with control neutrophils. In addition, we observed a strong reduction in 125I-labeled CXCL7 binding to neuraminidase-pretreated human neutrophils. Recently, Reutershan et al. identified a critical role for endothelial CXCR2 in the successful migration of neutrophils into LPS-stimulated lung tissue (26). We have not formally ruled out a role for endothelial CXCR2 in leukocyte adhesion and migration in stimulated cremaster muscle venules in vivo. However, we did not detect an effect of endothelial CXCR2 in mediating neutrophil transmigration in the chemotaxis assay using the brain endothelial cell line b.End5, suggesting that various endothelial compartments may differ in their ability to express functional CXCR2.
###end p 43
###begin p 44
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 347 350 347 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 939 942 939 942 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1782 1784 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1869 1872 1869 1872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2467 2469 2467 2469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 2613 2615 2613 2615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 2884 2887 2884 2887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2942 2945 2942 2945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2964 2967 2964 2967 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2977 2980 2977 2980 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 317 322 <span type="species:ncbi:9606">human</span>
###xml 423 428 <span type="species:ncbi:9606">human</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 1040 1045 <span type="species:ncbi:9606">human</span>
###xml 1251 1256 <span type="species:ncbi:10090">mouse</span>
###xml 1260 1265 <span type="species:ncbi:9606">human</span>
###xml 1873 1877 <span type="species:ncbi:10090">mice</span>
###xml 2888 2892 <span type="species:ncbi:10090">mice</span>
###xml 2946 2950 <span type="species:ncbi:10090">mice</span>
###xml 2981 2985 <span type="species:ncbi:10090">mice</span>
In a previous study, we reported that human CXCR2 is N-glycosylated at two distinct sites. This was shown by enzymatic deglycosylation and Western blotting of the immunoprecipitated receptor (9). In this study, we demonstrate that enzymatic removal of terminal sialic acids results in reduced CXCR2 ligand binding to human neutrophils. When using 125I-labeled CXCL7 as a high affinity CXCR2 ligand for binding studies with human neutrophils, we found a strong reduction in the affinity of CXCR2 when neutrophils were treated with neuraminidase, as shown by Scatchard analysis of the binding kinetics. In contrast, neuraminidase treatment of neutrophils neither affected the number of binding sites nor the expression level of CXCR2. These data suggest that sialic acids on neutrophils are required to maintain high ligand binding affinity rather than surface expression of the receptor. Although defective sialylation of CXCR2 in ST3Gal-IV-/- mice could not be directly demonstrated at the molecular level, we were able to demonstrate that human CXCR2 carries terminal sialic acids, which were sensitive to neuraminidase treatment. As a consequence of reduced receptor interaction, we observed decreased adhesion, transmigration, and degranulation of mouse or human leukocytes in response to CXCR2 ligands. To confirm that glycosylation defects would not affect the responsiveness of neutrophils in general, we stimulated neutrophils independent of CXCR2 using fMLP and CXCL4. Treatment with those proinflammatory mediators did not alter neutrophil responsiveness after desialylation. This does not exclude a requirement for terminal sialic acids for ligand binding by other chemokine receptors such as CCR5, for which an important role of glycosylation has also been demonstrated (10). However, CCR7-dependent migration of dendritic cells was not affected in ST3Gal-IV-/- mice (unpublished data), suggesting that sialylation cannot be considered a general requirement for optimal chemokine receptor-mediated events. Accordingly, our results suggest that posttranslational sialylation may be a new regulatory mechanism by which chemokine-triggered recruitment of some leukocyte subpopulations may occur. However, at present it remains unclear how cell type-specific expression of the different sialyltransferases contributes to chemokine receptor-mediated leukocyte adhesion. For the ST3Gal family of sialyltransferases, six different isoenzymes have been described (28). Previous studies of ST3Gal sialyltransferases have revealed different substrate specificity and tissue expression of the various isoenzymes (29). ST3Gal-IV shares substrate specificity mostly with ST3Gal-VI and, to a minor degree, with ST3Gal-III. This may indicate that ST3Gal-VI (besides ST3Gal-IV) could also be involved in the regulation of chemokine receptor-triggered leukocyte arrest. Currently, ST3Gal-VI-/- mice are not available. Future studies using ST3Gal-VI-/- mice and ST3Gal-IV-/-/ST3Gal-VI-/- mice will help to further characterize the role of sialylation on chemokine receptor function.
###end p 44
###begin p 45
Collectively, our findings provide novel evidence for a crucial role of the sialyltransferase ST3Gal-IV in CXCR2-mediated neutrophil adhesion and recruitment under inflammatory conditions. Besides initiating the development of new therapeutic strategies in the treatment of CXCR2-mediated diseases, these results should also serve in stimulating additional studies in elucidating the role of posttranslational sialylation/glycosylation on chemokine receptor function.
###end p 45
###begin title 46
MATERIALS AND METHODS
###end title 46
###begin title 47
Animals.
###end title 47
###begin p 48
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
ST3Gal-IV-/- mice and CXCR2-/- bone marrow chimeric mice were generated as previously described (12, 30) and housed in barrier facilities under specific pathogen-free conditions. Animal experiments were approved by the Regierungsprasidium Karlsruhe (AZ 35-9185.81/G-67/03), the Bezirksregierung Koln (AZ 50.203.2 AC37, 19/04), and the University of Virginia Animal Care and Use Committee,
###end p 48
###begin title 49
Reagents.
###end title 49
###begin p 50
###xml 235 255 234 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bordetella pertussis</italic>
###xml 568 569 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 29 32 <span type="species:ncbi:10116">rat</span>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 111 116 <span type="species:ncbi:10090">Mouse</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
###xml 235 255 <span type="species:ncbi:520">Bordetella pertussis</span>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
###xml 467 472 <span type="species:ncbi:10090">mouse</span>
E-selectin blocking mAb 9A9 (rat IgG1; 30 mug per mouse) was a gift from B. Wolitzky (MitoKor, San Diego, CA). Mouse keratinocyte-derived chemokine (CXCL1) and human CXCL8 were obtained from PeproTech and injected at 600 ng per mouse. Bordetella pertussis PTx was purchased from Sigma-Aldrich (4 mug per mouse), and rmP-selectin and rmICAM-1 were purchased from R&D Systems. In certain experiments, rmTNF-alpha (R&D Systems) was injected intrascrotally at 500 ng per mouse 3 h before intravital microscopy was begun. Biotinylated mAb to CXCR2 (clone RII115; reference 9) was provided by E. Brandt (Research Center Borstel, Borstel, Germany). Biotinylated MAL-II was obtained from Vector Laboratories.
###end p 50
###begin title 51
Intravital microscopy.
###end title 51
###begin p 52
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 449 454 <span type="species:ncbi:3750">Apple</span>
Intravital microscopy of the cremaster muscle was conducted as reported previously with an upright microscope (model 512815/20; Leica) with a saline immersion objective (SW 40/0.75NA) (8). Experiments were recorded via a charge-coupled device camera system (CF8/1; Kappa) on an S-VHS recorder (Panasonic). Supplemental videos were generated by digitizing and compressing the appropriate video sequences from recorded videotapes using Final Cut 5.1 (Apple) and Premiere Pro 1.5 (Adobe).
###end p 52
###begin title 53
Data analysis of intravital experiments.
###end title 53
###begin p 54
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 242 243 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b</sub>
###xml 254 255 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 305 306 304 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b</sub>
Microvascular parameters were measured using a digital image processing system (31). The rolling leukocyte flux fraction was defined as previously described (32) by dividing leukocyte rolling flux by total leukocyte flux, estimated as (WBC) vb pi (d/2) (2). (WBC) is the actual systemic leukocyte count, vb is the blood flow velocity, and d is the venular diameter.
###end p 54
###begin title 55
Whole-mount histology.
###end title 55
###begin p 56
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
To differentially count intravascular and extravascular leukocytes, cremaster muscle whole mounts were prepared as previously described (33). Leukocyte differential counts were assessed using a microscope with a 100x 1.4NA oil immersion objective (Carl Zeiss, Inc.).
###end p 56
###begin title 57
Thioglycollate-induced peritonitis model.
###end title 57
###begin p 58
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
Peritoneal recruitment of leukocytes was induced by intraperitoneal injection of 1 ml of freshly prepared thioglycollate (Sigma-Aldrich), as previously described (33). Some mice received 4 mug PTx 3 h before thioglycollate injection. 4 h after thioglycollate injection, mice were killed, and the peritoneum was rinsed with 5 ml of chilled PBS and massaged for 10 s. The total neutrophil count of the peritoneal lavage was assessed using Turks-stained samples.
###end p 58
###begin title 59
Ex vivo microflow chamber.
###end title 59
###begin p 60
###xml 93 95 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 97 99 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
Microflow chambers (20 x 200-mum cross section; VitroCom) were used as previously described (15, 34). 20 mug/ml rmP-selectin, 15 mug/ml rmICAM-1, and 15 mug/ml rmCXCL1 were immobilized in the chamber for 2 h at room temperature. Chambers were blocked for 1 h with 10% casein (Thermo Fisher Scientific) and connected to tubing (PE 10; Becton Dickinson), which was inserted into the carotid artery. On the other chamber end, a tube (PE 50; Becton Dickinson) was connected and used to control wall shear stress. Microscopy was conducted using a microscope (Axioskop; Carl Zeiss, Inc.) with a saline immersion objective (SW 20/0.5NA). Images were recorded over 6 min for each chamber with a charge-coupled device color video camera (DXC-390; Sony) connected to an S-VHS recorder.
###end p 60
###begin title 61
Flow cytometry.
###end title 61
###begin p 62
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 414 415 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 378 381 <span type="species:ncbi:10116">rat</span>
Expression of CXCR2 was analyzed on freshly isolated peripheral leukocytes from control and ST3Gal-IV-/- mice. After centrifugation and red blood cell lysis with PharM-Lyse 10x solution (BD Biosciences), cells were suspended in PBS/1% BSA solution and incubated in the dark with a PE-conjugated mAb against CXCR2, an allophycocyanin-conjugated mAb against GR-1, and appropriate rat isotype controls (0.5 mug per 106 cells; Becton Dickinson) for 30 min on ice. To study binding of CXCL8, blood leukocytes were incubated with different concentrations of CF-CXCL8 in the absence or presence of a 10-fold excess of unlabeled CXCL8 in PBS/1% BSA for 30 min on ice. Gated neutrophil populations were analyzed using a FACSCalibur or LSR II (both from BD Biosciences) with the FACSDiva software package (BD Biosciences).
###end p 62
###begin title 63
Transendothelial migration assay.
###end title 63
###begin p 64
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 462 463 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 695 719 683 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arthrobacter ureafaciens</italic>
###xml 734 735 722 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 695 719 <span type="species:ncbi:37931">Arthrobacter ureafaciens</span>
Transendothelial migration of neutrophils was analyzed as previously described (35). In brief, 5 x 105 bone marrow-isolated neutrophils were added on top of a bEnd.5 cell monolayer that had been grown for 2 d in transwells (5 x 104 bEnd.5 cells per well; Costar) with a 5-mum pore size, coated with 50 mug/ml laminin (Boehringer Mannheim). 16 h before adding neutrophils, bEnd.5 cells were stimulated with 5 nM TNF-alpha. Assays were run at 37degreesC and 10% CO2 for 30 min in presence of 40 ng/ml CXCL1 in the bottom chamber. Migrated neutrophils were collected for cell counting (CASY; Scharfe-System). In some experiments, WT control neutrophils were incubated with 0.1 U neuraminidase from Arthrobacter ureafaciens (Roche) per 106 cells at 37degreesC for 20 min.
###end p 64
###begin title 65
Enzymatic deglycosylation.
###end title 65
###begin p 66
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 220 235 220 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vibrio cholerae</italic>
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 220 235 <span type="species:ncbi:666">Vibrio cholerae</span>
Isolated human neutrophils of CXCR2-transfected HEK293 cells were suspended at 107 cells/ml in PBS containing 0.1% BSA and treated with the indicated dosages of recombinant N-glycosidase F or purified neuraminidase from Vibrio cholerae (both from Roche) for the indicated times. Subsequently, washed cells were investigated for radioligand binding and activation by chemoattractants, as described in Iodination of chemokines and binding assays.
###end p 66
###begin title 67
Immunoprocipitation and Western blotting.
###end title 67
###begin p 68
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 175 176 175 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 596 607 594 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V. cholerae</italic>
###xml 596 607 <span type="species:ncbi:666">V. cholerae</span>
HEK293 cells were transfected to express CXCR2 using lipofectamine (Invitrogen) and were used for immunoprecipitation of CXCR2, as previously described (9). In brief, 0.5 x 107 cells were suspended in 1 ml of ice-cold lysis buffer (PBS containing 1% Triton X-100 and a protease inhibitor mix; Roche) and incubated for 10 min. Cell lysates were cleared by centrifugation at 10,000 g for 10 min, and CXCR2 was precipitated with 5 mug/ml anti-CXCR2 antibody followed by the addition of 30 mul of protein A agarose (GE Healthcare). Washed precipitates were treated for 60 min with neuraminidase from V. cholerae at 37degreesC in PBS or left untreated. Subsequently, precipitates were analyzed by Western blotting for binding of biotinylated lectin MAL-II (20 mug/ml) or anti-CXCR2 antibody (2 mug/ml), which were detected by peroxidase-conjugated steptavidin (1:50,000; Roche) and addition of enhanced chemoluminescence substrate (GE Heathcare).
###end p 68
###begin title 69
Iodination of chemokines and binding assays.
###end title 69
###begin p 70
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 316 317 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 376 379 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 415 418 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
Chemokines were radiolabeled by iodination at tyrosine residues using the chloramine T method (17). Before iodination, CXCL7 was chemically modified by the introduction of tyrosine residues, as previously described (17). PMN were suspended at 107 cells/ml in Dulbecco's PBS (D-PBS)/2%BSA, and duplicate samples of 106 cells were incubated on ice for 2 h with 10 nmol/liter of 125I-labeled CXCL7 or 1 mumol/liter of 125I-labeled CXCL4 in the presence or absence of a 10-fold excess of unlabeled CXCL7 or CXCL4, respectively. After twofold washing and sedimentation through 10% sucrose in D-PBS, bound radioactivity was determined in a gamma counter, and unspecifically bound radioactivity determined in the presence of the unlabeled chemokines was subtracted.
###end p 70
###begin title 71
Degranulation assays.
###end title 71
###begin p 72
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 115 116 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 804 806 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human polymorphonuclear cells from peripheral blood were generated as previously described (36) and suspended at 107 cells/ml in D-PBS/0.1% BSA (low endotoxin BSA; Serva). Before the addition of secondary stimuli, cells were incubated at 37degreesC under agitation with 5 pg/ml cytochalasin B (Sigma-Aldrich) for the measurement of elastase release or with 9 ng/ml TNF-alpha for priming of lactoferrin release. Cells were then challenged with the secondary stimuli CXCL8 (1, 3, and 10 nM), CXCL7 (1, 3, 10, and 30 nM), CXCL4 (1, 3, and 10 muM), or fMLP (1, 3, and 10 nM) in D-PBS/0.1% BSA with 0.9 mM CaCI and 0.5 mM MgCI. After 30 min of incubation at 37degreesC, the cells were sedimented, and supernatants were monitored for elastase enzymatic activity or lactoferrin release as previously described (37). Release rates for elastase and lactoferrin were expressed as the percentages of total content in detergent-treated PMN lysates prepared in 0.1% hexadecyltrimethylammonium bromide.
###end p 72
###begin title 73
Statistics.
###end title 73
###begin p 74
###xml 350 351 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The Sigma Stat 2.0 software package (SPSS Inc.) was used for statistical analysis. Microvascular parameters and leukocyte differentials between groups and treatments were compared with the one-way analysis of variance on ranks (Kruskal-Wallis) with a multiple pairwise comparison test (the Dunn's or Tukey test, as appropriate) or with the Student's t test, as appropriate. Statistical significance was set at P < 0.05, indicated by *.
###end p 74
###begin title 75
Online supplemental material.
###end title 75
###begin p 76
###xml 152 155 152 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 338 341 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 352 357 348 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">bm&#8722;/&#8722;</sup>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 462 467 <span type="species:ncbi:9606">human</span>
Intravital microscopy was applied in Videos 1 and 2 to visualize leukocyte arrest in unstimulated cremaster muscle venules of WT (Video 1) and ST3Gal-IV-/- (Video 2) mice before and after systemic injection of 600 ng CXCL8. Fig. S1 illustrates leukocyte rolling in untreated and TNF-alpha-treated cremaster muscle venules of WT, ST3Gal-IV-/-, and CXCR2bm-/- mice. Fig. S2 demonstrates the effect of enzymatic desialylation on expression and function of CXCR2 on human neutrophils. Online supplemental material is available at .
###end p 76
###begin title 77
Supplementary Material
###end title 77
###begin title 78
[Supplemental Material Index]
###end title 78
###begin p 79
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
We thank Juergen Bieling for help in preparing the videos, Birgit Kempe for excellent technical assistance, and Dr. Barry Wolitzky for providing the mouse E-selectin blocking antibody 9A9.
###end p 79
###begin p 80
This work was supported by German Research Foundation grants SP621/3-1 (to M. Sperandio), Lu 869/1-3 (to A. Ludwig), and AZ428/2-1 (to A. Zarbock); by National Institutes of Health grants HL-64381 and HL-54136 (to K. Ley), P01-HL57345 (to J.D. Marth), and CA-118182 (to L.G. Ellies); by LMU Innovativ BioImaging; by the Interdisziplinares Zentrum fur Klinische Forschung (IZKF) Biomat, University Hospital RWTH Aachen (to A. Ludwig); and by IZKF, University of Muenster (to D. Vestweber).
###end p 80
###begin p 81
The authors have no conflicting financial interests.
###end p 81

